arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Indivior Pharmaceuticals, Inc.

INDV
$35.87 ▼ -0.33 (-0.91%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
19 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
42
Health
Weak
Moderately Bullish
auto_awesome

Analytical Summary

Indivior Pharmaceuticals, Inc. shows strong fundamentals with top-quartile Profit Margin (%) and Debt to Equity. However, watch Return on Common Equity (%) which shows concerning trends. Overall, the data suggests a moderately positive outlook with manageable risks.

Market Cap $4.3B
Dividend Yield —
Revenue Growth 13.6% ↘
Op. Margin 46.6% ↗
ROIC 43.7% ↗
FCF / Share $1.87 ↗
Trailing P/E 35.2x
Price / Book —
FCF Yield 5.2%
Debt / Equity -2.34
info Valuation on last close. End-of-day price, Sep 23, 2026.

19-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$343.00M
↑ +13.6% —
Net Income Profit after all expenses
$89.00M
↑ +89.4% —
Operating Margin Operating profit as % of sales
46.6%
↑ +7.9% 77th
FCF / Share Free cash flow per share
$1.87
↑ +897.7% —
Long-Term Debt Long-term obligations
$487.00M
— +0.2% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓
56
Returns
2
Financial Health ↓
89
Cash Quality
14

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 5 years · 19 quarters